Posted on

Eli Lilly targets buying spree in 2020

Looking to build up its pipeline of future products, Eli Lilly (NYSE:LLY) aims to announce a $1B-5B deal for each quarter of 2020.

The acquisitions will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters.

The spree has already started. Last week, Eli Lilly announced a deal to buy dermatology products maker Dermira for $1.1B.

Source: M A News on Seeking Alpha